KRAS and pancreatic adenocarcinoma: The rates of digestive adenocarcinoma without APC, KRAS, and CDKN2A alterations in patients with biliary tract, gastric, colorectal, and pancreatic adenocarcinomas were 54.8%, 21.0%, 18.5%, and 5.6%, respectively (Figure S7f).